BRAF and ganglioglioma: Pekmezci et al. note that in the majority of cases, ganglioglioma showed BRAF alterations however, in tumors lacking identified BRAF mutations, 69% demonstrated mutations that are predicted to activate the MAPK pathway such as alterations in KRAS, FGFR2, NF1, and RAF1 [4].